A short term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics

Abstract

Kenneth Blum1,3,8,9,*,#, Thomas JH Chen2, Lonna Williams3, Amanda LC Chen2,*, William B. Downs3, Roger L. Waite3, T. Huntington3, Simon Sims4, Thomas Prihoda5, Patrick Rhoads6, Jeffrey Reinking7, Dasha Braverman8, Mallory Kerner8, Seth H. Blum9, Brien Quirk10, Eric R Braverman11 Department of Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA Chang Jung Christian University, Tainan, Taiwan Republic of China Department of Nutrigenomics, LifeGen®, Inc. La Jolla, California, USA 4 DNA Services of America, Lafayette, Louisiana, USA 5 Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA 6 Central Valley Comprehensive Obesity Clinic, Modesto, California, USA Department of Medicine, University of California School of Medicine at Davis, Davis California, USA Department of Clinical Neurology, Path Medical and Research Foundation, New York, New York, USA 9 Department of Psychoneurogenetics, Synaptamine, Inc., San Antonio, Texas, USA 10 Draco Natural Products, Inc. Eugene, Oregon, USA Department of Neurosurgery, Weill Cornell College of Medicine, New York, New York, USA __________________________________________________________________________________ *Correspondence: Kenneth Blum, Ph.D., Department of Physiology & Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, 27157, USA; Tel: [phone]; e-mail [e-mail] Amanda LC Chen, Chang Jung Christian University, Tainan, Taiwan Republic of China: e-mail [e-mail] #All reprint request to Kenneth Blum e-mail: [e-mail]